Skip to main content

Tecartus genetically modified autologous T cells for infusion Images

Generic Name: brexucabtagene autoleucel

This medication has been identified as Tecartus genetically modified autologous T cells for infusion. It is supplied by Kite Pharma, Inc.

Tecartus is used in the treatment of Mantle Cell Lymphoma; Acute Lymphoblastic Leukemia and belongs to the drug class miscellaneous antineoplastics. Tecartus genetically modified autologous T cells for infusion is not a controlled substance under the Controlled Substances Act (CSA).

Images of medication

Tecartus genetically modified autologous T cells for infusion medicine
Tecartus genetically modified autologous T cells for infusion medicine

Tecartus

Generic Name
brexucabtagene autoleucel
Strength
genetically modified autologous T cells for infusion
Availability
Prescription only
Drug Class
Miscellaneous antineoplastics
CSA Schedule
Not a controlled drug
Labeler / Supplier
Kite Pharma, Inc.
National Drug Code (NDC)
71287-0219

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.